{
    "clinical_study": {
        "@rank": "127614", 
        "acronym": "ACH15", 
        "arm_group": [
            {
                "arm_group_label": "ACH15 - 50mg capsule", 
                "arm_group_type": "Experimental", 
                "description": "ACH15 50mg capsule by mouth single dose (Group 1)"
            }, 
            {
                "arm_group_label": "ACH15 - 250 mg capsule", 
                "arm_group_type": "Experimental", 
                "description": "ACH15 250mg capsule by mouth as single dose(Group 2)"
            }, 
            {
                "arm_group_label": "ACH15 - 500mg capsule", 
                "arm_group_type": "Experimental", 
                "description": "ACH15 500mg capsule by mouth in a single dose(Group 3)"
            }, 
            {
                "arm_group_label": "ACH15 - 1000 mg (two 500mg capsule)", 
                "arm_group_type": "Experimental", 
                "description": "ACH15 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)"
            }, 
            {
                "arm_group_label": "ACH15 - 2000 mg (four 500 mg capsule)", 
                "arm_group_type": "Experimental", 
                "description": "ACH15 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)"
            }, 
            {
                "arm_group_label": "ACH15 - 500 mg (twice a day for 7 days)", 
                "arm_group_type": "Experimental", 
                "description": "ACH15 500mg capsule by mouthn twice a day for seven days (Group 6)"
            }, 
            {
                "arm_group_label": "Placebo - 250 mg capsule", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 250mg capsule by mouth single dose (Group 2)"
            }, 
            {
                "arm_group_label": "Placebo - 500 mg capsule", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 500mg capsule by mouth in a single dose(Group 3)"
            }, 
            {
                "arm_group_label": "Placebo - 1000 mg (two 500mg capsule)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 500mg capsule by mouth, two 500 mg capsules once as a single dose(Group 4)"
            }, 
            {
                "arm_group_label": "Placebo 2000 mg (four 500mg capsule)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 500mg capsule by mouth, four 500 mg capsules once as a single dose(Group 5)"
            }, 
            {
                "arm_group_label": "Placebo - 500 mg (twice a day for 7 days)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 500mg capsule by mouthn twice a day for seven days (Group 7)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is evaluate the safety and tolerability parameters regarding the\n      new drug in healthy men and evaluate the pharmacokinetics parameters after one dose and\n      multiple doses of the new drug."
        }, 
        "brief_title": "Study to Assess Tolerability, Safety and Pharmacokinetics of a New Drug", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Safety", 
            "Pharmacokinetics", 
            "Tolerability", 
            "Healthy Men"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male patient, aged between 18 and 50 years;\n\n          -  Body weight \u2265 50 kg and BMI \u2265 18.5 kg/m2 and \u2264 30 kg/m2;\n\n          -  Healthy men accordance with their historical and tests;\n\n          -  Healthy subject with laboratory results within the normal range or within the\n             parameters accepted by the clinical protocol\n\n          -  Negative results for parasitological stool examination performed in the clinical\n             study;\n\n          -  Subject of research with laboratory results within the normal range for urinalysis\n             collected before the first visit;\n\n          -  Research subjects allocated in Group 6 with endoscopy within the normal range;\n\n        Exclusion Criteria:\n\n          -  History of gastrointestinal disease, hepatic, renal, cardiovascular, pulmonary,\n             neurologic, hematologic, diabetes or glaucoma;\n\n          -  Evidence on clinical examination or physical or complement, organ dysfunction or any\n             clinically significant deviation from normality;\n\n          -  History of use of psychotropic drugs or excessive alcohol consumption (more than two\n             units of alcohol per day, one unit being equivalent to one cup (200 mL) of brew or a\n             dose (50) mL of distilled beverage) or having difficulty to abstain during the study;\n\n          -  Use of any medication two (2) weeks prior to inclusion of the research subject in the\n             study;\n\n          -  Regular smokers or who quit less than one (1) year;\n\n          -  History of food allergy or hyperreactivity to medications or foods;\n\n          -  HIV positive for HIV;\n\n          -  Being  positive for Hepatitis B;\n\n          -  Being positive for hepatitis C;\n\n          -  Testing positive for Helicobacter pilorum;\n\n          -  Using substances modulating hepatic microsomal activity within thirty (30) days prior\n             to entry of the subject of research in the clinical study (date of signing the\n             consent form);\n\n          -  Having donated blood (blood volume higher than 500 mL) within four (4) months\n             preceding the date of signing the consent form;\n\n          -  Subject with a history of hypersensitivity to any component of the investigational\n             product;"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702675", 
            "org_study_id": "ACH-HML-01(03/12)"
        }, 
        "intervention": [
            {
                "arm_group_label": "ACH15 - 50mg capsule", 
                "description": "ACH15 50mg capsule", 
                "intervention_name": "ACH15 50 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ACH15 - 250 mg capsule", 
                "description": "ACH15 250mg capsule", 
                "intervention_name": "ACH15 250 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ACH15 - 500mg capsule", 
                "description": "ACH15 500 mg capsule", 
                "intervention_name": "ACH15 500mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ACH15 - 1000 mg (two 500mg capsule)", 
                "description": "ACH15 500mg capsule - two 500mg capsules in single dose", 
                "intervention_name": "ACH15 - 1000mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ACH15 - 2000 mg (four 500 mg capsule)", 
                "description": "ACH15 500mg capsule (four 500mg capsules in one dose)", 
                "intervention_name": "ACH15 - 2000mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "ACH15 - 500 mg (twice a day for 7 days)", 
                "description": "ACH15 - 500mg twice a day for 7 days", 
                "intervention_name": "ACH15 - 500mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo - 250 mg capsule", 
                "description": "Capsule manufactured to mimic ACH15 250 mg capsule", 
                "intervention_name": "Placebo 250 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo - 500 mg capsule", 
                    "Placebo - 500 mg (twice a day for 7 days)"
                ], 
                "description": "Capsule manufactured to mimic ACH15 500 mg capsule", 
                "intervention_name": "Placebo 500mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo - 1000 mg (two 500mg capsule)", 
                "description": "Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)", 
                "intervention_name": "Placebo 1000mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo 2000 mg (four 500mg capsule)", 
                "description": "Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)", 
                "intervention_name": "Placebo 2000mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Placebo - 500 mg capsule", 
                    "Placebo - 500 mg (twice a day for 7 days)"
                ], 
                "description": "Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)", 
                "intervention_name": "Placebo 500mg", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Safety", 
            "Pharmacokinetics", 
            "Tolerability", 
            "Healthy men"
        ], 
        "lastchanged_date": "October 5, 2012", 
        "location": {
            "contact": {
                "last_name": "Ney Ney Carter do Carmo , Borges", 
                "phone": "+55 19 3233 7300"
            }, 
            "facility": {
                "address": {
                    "city": "Campinas", 
                    "country": "Brazil", 
                    "state": "S\u00e3o Paulo", 
                    "zip": "13073-200"
                }, 
                "name": "Synchrophar"
            }, 
            "investigator": {
                "last_name": "Ney Carter do Carmo Borges, Doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "11", 
        "official_title": "Phase I, Monocentric, Double-blind, Randomized Study to Assess Tolerability, Safety and Pharmacokinetics of ACH15 After Single Dose and Multiple Doses in Healthy Male Volunteers", 
        "overall_contact": {
            "email": "medney@synchrophar.com", 
            "last_name": "Ney Cartes do Carmo Borges, Doctor", 
            "phone": "+55 19 3233 7300"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "Brazil: Ethics Committee", 
                "Brazil: National Health Surveillance Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Eletrocardiogram", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "measure": "Echocardiography (participants included in Group 6)", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Blood analysis to evaluate drug pharmacokinetics at Group 1 to 5: 30 minutes and 05 minutes before dose and 00h10 min,  00h15 min, 00h30 min, 00h45 min, 01h, 01h15min, 01h30min, 01h45min, 02h, 02h15min, 02h30min, 02h45min, 03h, 03h15min, 03h30min, 03h45min, 04 h, 04h15min, 04h30min, 04h45min, 05h, 05h30min, 06 h, 08 h, 10 h, 12h, 16h, 24 h e 48hours post-dose", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "31 time points up to 2 days"
            }, 
            {
                "description": "Image exam to evaluate the drug safety", 
                "measure": "High digestive endoscopy (participants included at Group 6)", 
                "safety_issue": "Yes", 
                "time_frame": "8 days"
            }, 
            {
                "description": "Blood will be colected to evatuate the drug safety by analysis of biochemical profile", 
                "measure": "Blood analysis", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Blood analysis to evaluate drug pharmacokinetics at Group 6:00:30 min before dose, 00h20min, 00h40min, 01h, 01h15min, 01h30min, 01h45min, 02h, 02h15min, 02h30min, 02h45min, 03h, 03h15min, 03h30min, 03h45min, 04h, 04h15min, 04h30min, 04h45min, 05h, 05h30min, 06h, 08h, 10h, 12h, 14h, 18h, 24h, 26h, 30h, 36h, 38h, 42h, 48h, 50h, 54h, 60h, 62h, 66h, 72h, 74h, 78h, 84h, 86h, 90h, 96h, 98h, 102h, 108h, 110h, 114h, 120h, 122h, 126h, 132h, 134h, 138h, 144h, 146h, 150h, 156h, 158h, 162h, 168h, 174h, 180h e 192h post-dose.", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "67 pint time over 8 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702675"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Ache Laboratorios Farmaceuticos S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ache Laboratorios Farmaceuticos S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}